Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/s00520-011-1230-9.pdf
Reference56 articles.
1. Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14–27
2. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176
3. Berenson JR, Lichtenstein A, Porter L et al (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia study group. J Clin Oncol 16:593–602
4. Lipton A (2003) Bisphosphonates and metastatic breast carcinoma. Cancer 97:848–853
5. Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082–1090
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study;Bone Reports;2024-09
2. Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients;Bone Reports;2021-12
3. Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey;Supportive Care in Cancer;2021-05-22
4. Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey;Journal of Bone Oncology;2021-02
5. Practical Update for the Use of Bone-Targeted Agents in Patients with Bone Metastases from Metastatic Breast Cancer or Castration-Resistant Prostate Cancer;Current Oncology;2020-08-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3